Gilead Sciences NASDAQ: GILD has filed 13-F forms with the SEC as an investor. Gilead Sciences is itself a publicly traded company. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. For more information on Gilead Sciences stock, visit the Gilead Sciences stock profile here.
Investment Activity
- Gilead Sciences has $1.28 billion in total holdings as of June 30, 2025.
- Gilead Sciences owns shares of 14 different stocks, but just 3 companies or ETFs make up 80% of its holdings.
- About 0.19% of the portfolio was sold this quarter.
- This quarter, Gilead Sciences has purchased 14 new stocks and bought additional shares in 0 stocks.
- Gilead Sciences sold shares of 3 stocks and completely divested from 0 stocks this quarter.
Largest Holdings
- ASSEMBLY BIOSCIENCES INC
- $40,035,615
Largest Sales this Quarter
- IKENA ONCOLOGY INC
- 810,611 shares (about $1.09M)
- KALARIS THERAPEUTICS INC
- 405,484 shares (about $1.08M)
